WearLinq is a medtech startup redefining how cardiovascular disease is diagnosed by introducing the first FDA-cleared, wireless 6-lead EKG wearable patch. Their device allows continuous, ambulatory, and reimbursable monitoring of cardiac arrhythmias and other conditions — replacing outdated Holter and single-lead solutions. With $3M+ ARR, strong insurance coverage, and a credible path to $100M+ revenue by 2028, WearLinq is positioned as a premium platform for remote heart health diagnostics.